Related Experiment Videos
Pharmacology: antiplatelet and antithrombin therapy in acute coronary syndromes
1The Cleveland Clinic Foundation, Ohio, USA.
Insights
Coronary artery disease causes millions of deaths annually. This review discusses antiplatelet and antithrombin agents, crucial for treating acute myocardial infarctions (AMI) and reducing cardiovascular disease morbidity.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) is a leading cause of mortality in the United States and worldwide.
- Acute myocardial infarctions (AMI) affect 1.25 million Americans annually, with 500,000 deaths, highlighting the urgent need for effective treatments.
- Atherosclerotic cardiovascular disease poses significant health risks, necessitating interventions to reduce patient morbidity.
Purpose of the Study:
- To review current antiplatelet and antithrombin agents used in clinical practice.
- To highlight the role of these agents in managing acute myocardial infarction (AMI) and atherosclerotic cardiovascular disease.
- To provide an overview of therapeutic options for reducing morbidity and mortality associated with coronary artery disease.
Main Methods:
- Literature review of antiplatelet and antithrombin agents.
- Analysis of clinical applications in managing acute myocardial infarction (AMI).
- Examination of agents used for patients with atherosclerotic cardiovascular disease.
Main Results:
- Inhibitors of platelet function are associated with reduced morbidity in patients with atherosclerotic cardiovascular disease.
- Thrombolytic therapy for reperfusion of occluded coronary arteries has significantly decreased mortality and morbidity from AMI.
- Several antiplatelet and antithrombin agents are currently utilized in clinical settings in the United States.
Conclusions:
- Antiplatelet and antithrombin agents play a vital role in the management of acute myocardial infarction (AMI) and coronary artery disease (CAD).
- These pharmacological interventions are essential for reducing mortality and morbidity in patients with cardiovascular conditions.
- Continued research and clinical application of these agents are critical for improving outcomes in patients at risk for or experiencing cardiovascular events.
Abstract:
Coronary artery disease is the leading cause of death in the United States. According to estimates, 1.25 million acute myocardial infarctions (AMI) occur in the United States each year, 500,000 of which result in death (half of those resulting from sudden death within the first hour). Worldwide, the annual death toll from AMI is approximately 4 million. Inhibitors of platelet function have been associated with decreased morbidity in patients with atherosclerotic cardiovascular disease. Reperfusion of occluded coronary arteries via thrombolytic therapy has markedly reduced mortality and morbidity resulting from events of acute myocardial infarction. This article addresses several antiplatelet and antithrombin agents currently in clinical use throughout the United States.